The Clinical Study And Influencing Factors Of Efficacy Analysis On Neoadjuvant Chemotherapy With Combination Of Docetaxel And Pharmorubicin For Locally Adwanced Breast Cancer

[Background] Breast cancer is one of the common female malignancy. Due to changes in lifestyle, the incidence is rising. Breast cancer is relatively sensitive to chemotherapy, chemotherapy; including neoadjuvant chemotherapy in breast cancer treatment process plays an important role.[Obective] To evaluate the clinical efficacy and toxicity of combination neoadjuvant chemotherapy with docetaxel and pharmonlbicin in the treatment of locally advanced breast cancer, and analyze the impact of neoadjuvant chemotherapy.[Methods] From June2009to March2012,36breast cancer patients who have been pathologically confirmed by coreneedle biopsy were treated with neoadjuvant chemotherapy before operation.Docetaxel75m//m2plus pharmorubicin80mg/m2were administered as intravenous infusion on the first day of each3-week cycle. Accepted2to4cycles of the treatment, the patients were underwent surgery after12to16days.[Results] The overall response rate(RR)was72.2%(26/36).The complete clinical response rate(CR)was19.4%(7/36).The partial response rate(PR)was52.8%(19/36).The stable disease(SD)rate was16.7%(6/36).The progress disease(PD)rate was5.6%(2/36).The pathological complete rate(pCR) was5.6%(2/36). The major toxic reactions of the therapy were neutropenia, alopecia, nausea and vomit.26patients(72.2%) suffered with grade2to4neutropenia.23patients suffered with varying degrees of alopecia.26patients (72.2%)accepted supportive treatment of G-CSF.Septicemia and death were not occurred in this study.[Conclusion] The combination neoadjuvant chemotherapy with docetaxel and phannonlbicin is an effective method to treat breast cancer and the toxicities are tolerable. The tumor size is most closely related factors that affect the efficacy of ET chemotherapy, in addition that the ER、PR expression also bring a certain degree of influence.